Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

Core Insights - Madrigal Pharmaceuticals, Inc. will participate in three upcoming investor conferences, showcasing its commitment to engaging with investors and stakeholders in the healthcare sector [1][2][3] Conference Participation - The company will present at the Jefferies Global Healthcare Conference in London on November 20, 2025, at 8:30 A.M. GMT [1] - Madrigal will also participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, at 4:15 P.M. ET [2] - Additionally, the company is scheduled to present at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 1:30 P.M. ET [3] Company Overview - Madrigal Pharmaceuticals focuses on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with significant unmet medical needs [4] - The company's lead medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist, and is the first and only medication approved by both the FDA and European Commission for treating MASH with moderate to advanced fibrosis (F2 to F3) [4] - An ongoing Phase 3 outcomes trial is assessing Rezdiffra for the treatment of compensated MASH cirrhosis (F4c) [4]